- Ardent Health Partners, Inc. (ARDT, Financial) reported a 4.0% year-over-year revenue growth in Q1 2025, amounting to $1.50 billion.
- Net income attributable to Ardent Health grew to $41 million, with diluted earnings per share rising to $0.29 from $0.21 in Q1 2024.
- The company reaffirmed its full-year 2025 financial guidance, forecasting total revenue between $6,200 million and $6,450 million.
Ardent Health Partners, Inc. (ARDT), a major healthcare provider focused on urban communities, announced its financial results for the first quarter of 2025. The company experienced a 4.0% increase in total revenue, reaching $1.50 billion, compared to the same period in the previous year. The revenue growth was primarily driven by a 2.7% increase in adjusted admissions and a 1.2% growth in net patient service revenue per adjusted admission.
Net income attributable to Ardent Health surged to $41 million, translating to $0.29 per diluted share, up from $27 million, or $0.21 per diluted share, in the first quarter of 2024. The company's adjusted EBITDA also saw a year-over-year growth of 2.5%, amounting to $98 million.
Admissions increased by 7.6% year-over-year, influenced by a robust flu season, while adjusted admissions witnessed a 2.7% growth. Inpatient surgeries rose by 3.4%, further contributing to the overall positive performance, despite a 0.7% decline in total surgeries.
Ardent Health is maintaining its full-year 2025 financial guidance, projecting total revenue to be between $6.2 billion and $6.45 billion. The company also expects adjusted EBITDA to range from $575 million to $615 million. This outlook includes anticipated benefits from state-directed payment programs in Oklahoma and New Mexico.
Reflecting on the results, Marty Bonick, President and CEO of Ardent Health, emphasized the successful execution of strategic priorities, highlighting progress in strategic growth initiatives and operational excellence. Bonick noted a 60 basis point reduction in supply costs as a percent of revenue and expressed confidence in pursuing value-enhancing transactions with a solid balance sheet.
The company's available liquidity was reported at $790 million, with cash and cash equivalents of $495 million and total debt standing at $1.1 billion as of March 31, 2025.
